Acta Diabetologica

, Volume 32, Issue 2, pp 131–134 | Cite as

Effect of recombinant human growth hormone treatment on insulin-like growth factor (IGF-I) levels in insulin-dependent diabetic patients

  • M. I. Wurzburger
  • G. M. Prelevic
  • P. H. Sönksen
  • M. Wheeler
  • L. Balint-Peric


Basal and recombinant human growth hormone (rhGH)-stimulated insulin-like growth factor (IGF-I) levels were studied in 19 insulin-dependent diabetic patients and 4 healthy subjects. Diabetic patients were divided according to glucagon test result into CpN (10 patients without residual beta cell activity) and CpP (9 patients with preserved beta-cell activity) groups, and according to age into three groups (A=21–30 years; B=31–40 years; C=41–50 years). All control subjects belonged to group B. Blood glucose and growth hormone were measured at hourly intervals and IGF-I every 6 h during 24 h before and after 7 days treatment with 4 IU of rhGH given subcutaneously at 8 p.m. The age-related decrease in basal IGF-I levels was evident in both CpN and CpP groups of diabetic patients. IGF-I net increase with rhGH treatment was variable and insignificant in comparison with basal value without age-related differences in CpN diabetics. Progressively larger age-related increases in IGF-I concentrations were observed in CpP diabetic patients. This study indicates impairment of hepatic IGF-I generation capacity in diabetic patients without residual beta-cell activity and the importance of simultaneous actions of portal insulin and GH on hepatic IGF-I production.

Key words

Type I diabetes mellitus Human recombinant growth hormone Insulin-like growth factor I Residual beta-cell activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muller EE, Clinical implications of growth hormone feedback mechanisms. Horm Res 33 [Suppl 4]:90–96, 1990Google Scholar
  2. 2.
    Hansen AP, Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest 49:1467–1478, 1970Google Scholar
  3. 3.
    Kjeldsen H, Hansen AP, Twenty-four hour serum hormone levels in maturity-onset diabetics. Diabetes 24:977–982, 1975Google Scholar
  4. 4.
    Herschopf R, Plotnick LP, Kaya K, Benedict GW, Hadji-Georgopoulos A, Margiolis S, Kowarski KA, Short-improvement in glycaemic controls utilising continuous subcutaneous insulin infusion: the effect on 24-hour integrated concentrations of counter regulatory hormones and plasma lipids in insulin dependent diabetes mellitus. J Clin Endorinol Metab 54:504–509, 1982Google Scholar
  5. 5.
    Arias P, Kerner W, de la Fuente A, Pfeiffer EF, Abnormal growth hormone levels in insulin-dependent patients under continuous subcutaneous insulin infusion and intensified conventional treatment. Acta Endocrinol (Copenh) 107:250–255, 1984Google Scholar
  6. 6.
    Asplin CM, Faria ACS, Carlsen EC, Ewans WS, Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 69:239–245, 1989Google Scholar
  7. 7.
    Wurzburger MI, Prelevic GM, Sönksen PH, Peric LA, Till S, Morris RW, The effects of improved blood glucose on growth hormone and cortisol secretion in insulin-dependent diabetes mellitus. Clin Endocrinol 32:787–797, 1990Google Scholar
  8. 8.
    Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, Sherwin RS, Insulin-infusion-pump treament of diabetes: influence of improved metabolic control on plasma somatomedins levels. N Engl J Med 305:303–307, 1981Google Scholar
  9. 9.
    Horner JM, Kemp SF, Hintz R, Growth hormone and somatomedins in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 53:1148–1153, 1981Google Scholar
  10. 10.
    Shaper NC, Tamsma JT, Sluiter WJ, Roelse H, Reitsma WD, Doorenbos H, Growth hormone auto regulation in type I diabetes mellitus. Acta Endocrinol (Copenh) 122 [Suppl]:32–39, 1990Google Scholar
  11. 11.
    Teale JD, Marks V, The measurements of insulin-like growth factor I: clinical application and significance. Ann Clin Biochem 23:413–424, 1986Google Scholar
  12. 12.
    Wurzburger MI, Prelevic GM, Sönksen PH, Balin-Peric LA, Growth hormone level in patients with type I diabetes is age related. Diabetic Med 10:159–161, 1993Google Scholar
  13. 13.
    Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming AG, Bain RP, Impaired growth hormone secretion in the adult population. J Clin Invest 67:1361–1369, 1981Google Scholar
  14. 14.
    Ho KY, Hoffman DM, Physiology of growth hormone (GH) secretion: implication for diagnosis of GH deficiency in adults. In: Laron Z, Butenandt O (eds) Growth hormone replacement therapy in adults—pros and cons. Freund Publishing House, Tel Aviv, pp5–16, 1993Google Scholar
  15. 15.
    Merimee TJ, Zapf J, Insulin-like growth factors in adult diabetics. In: Martin Spencer E (ed) Insulin-like growth factors—somatomedins. de Gruyter Berlin, pp 295–298, 1983Google Scholar
  16. 16.
    Amiel SA, Sherwin RS, Hintz RJ, Gertner GC, Press M, Tamborlane WV, Effects of diabetes and its control on insulin-like growth factors in the young subjects with type I diabetes. Diabetes 33:1175–1179, 1984Google Scholar
  17. 17.
    Merimee TJ, Gardner DF, Zapf J, Froesch ER, Effect of glycaemic control on serum-insulin growth factors in diabetes mellitus. Diabetes 33:790–793, 1984Google Scholar
  18. 18.
    Rieu M, Binoux M, Serum levels of insulin-like growth factor (IGF) and IGF binding protein in insulin-dependent diabetics during an episode of severe metabolic decompensation and the recovery phase. J Clin Endocrinol Metab 60:781–785, 1985Google Scholar
  19. 19.
    Wurzburger MI, Prelevic GM, Sönksen PH, Balint-Peric LA, Wheeler M, The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes. J Clin Endocrinol Metab 77: 267–272, 1993Google Scholar
  20. 20.
    Lanes L, Recker B, Fort P, Deshitz F, Impaired somatomedins generation test in children with insulin-dependent diabetes mellitus. Diabetes 34:156–160, 1985Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • M. I. Wurzburger
    • 1
  • G. M. Prelevic
    • 1
  • P. H. Sönksen
    • 2
  • M. Wheeler
    • 3
  • L. Balint-Peric
    • 1
  1. 1.Endocrinology Department‘Zvezdara’ University Medical CentreBelgrade, BelgradeYugoslavia
  2. 2.Department of Medicine, United Medical and Dental Schools of Guy's and St. Thomas' HospitalSt. Thomas' HospitalLondonUK
  3. 3.Chemical Pathology, United Medical and Dental Schools of Guy's and St. Thomas' HospitalSt. Thomas' HospitalLondonUK

Personalised recommendations